These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 9410065

  • 1. [in vitro activity of carbapenems against Enterobacteriaceae and Pseudomonas aeruginosa hyperproducers of group 1 chromosomal beta-lactamases].
    Martínez-Beltrán J, Calderón C, Sierra MP, Alvarez M, Cantón R.
    Enferm Infecc Microbiol Clin; 1997 Sep; 15 Suppl 1():20-6. PubMed ID: 9410065
    [Abstract] [Full Text] [Related]

  • 2. [In vitro antibacterial activity and beta-lactamase stability of meropenem].
    Poiată A, Tuchiluş C, Bădicuţ I, Buiuc D.
    Rev Med Chir Soc Med Nat Iasi; 2003 Sep; 107(3):589-94. PubMed ID: 14756067
    [Abstract] [Full Text] [Related]

  • 3. In-vitro activity of biapenem, compared with imipenem and meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanisms.
    Chen HY, Livermore DM.
    J Antimicrob Chemother; 1994 May; 33(5):949-58. PubMed ID: 8089068
    [Abstract] [Full Text] [Related]

  • 4. Comparative in-vitro activity of meropenem against clinical isolates including Enterobacteriaceae with expanded-spectrum beta-lactamases.
    Chanal C, Sirot D, Chanal M, Cluzel M, Sirot J, Cluzel R.
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():133-41. PubMed ID: 2808205
    [Abstract] [Full Text] [Related]

  • 5. WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases.
    Mushtaq S, Vickers A, Woodford N, Livermore DM.
    J Antimicrob Chemother; 2017 Jun 01; 72(6):1688-1695. PubMed ID: 28333319
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Meropenem: activity against resistant gram-negative bacteria and interactions with beta-lactamases.
    Sanders CC, Sanders WE, Thomson KS, Iaconis JP.
    J Antimicrob Chemother; 1989 Sep 01; 24 Suppl A():187-96. PubMed ID: 2808207
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. In vitro activity of meropenem against ciprofloxacin-resistant enterobacteriaceae and Pseudomonas aeruginosa.
    Garcia-Rodriguez JA, Blazquez AM, Fresnadillo MJ, Garcia Sanchez E, Garcia Sanchez JE, Trujillano Martin I.
    J Chemother; 1996 Oct 01; 8(5):358-64. PubMed ID: 8957715
    [Abstract] [Full Text] [Related]

  • 11. Multicentre comparative study on the antibacterial activity of FK-037, a new parenteral cephalosporin.
    Martínez-Beltrán J, Cantón R, Liñares J, García de Lomas J, Gimeno C, Tubau F, Baquero F.
    Eur J Clin Microbiol Infect Dis; 1995 Mar 01; 14(3):244-52. PubMed ID: 7614970
    [Abstract] [Full Text] [Related]

  • 12. Imipenem and cephem resistant Pseudomonas aeruginosa carrying plasmids coding for class B beta-lactamase.
    Minami S, Akama M, Araki H, Watanabe Y, Narita H, Iyobe S, Mitsuhashi S.
    J Antimicrob Chemother; 1996 Mar 01; 37(3):433-44. PubMed ID: 9182100
    [Abstract] [Full Text] [Related]

  • 13. Use of Etests with carbapenems for Gram-negative rods producing beta-lactamases.
    Kocazeybek BS, Arabaci U.
    Int J Antimicrob Agents; 2002 Feb 01; 19(2):159-62. PubMed ID: 11850170
    [Abstract] [Full Text] [Related]

  • 14. Use of cefotaxime or ceftazidime susceptibility tests for predicting susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa.
    Heym B, Lacroix O, Péan Y, Gertner J, Nicolas MH, Jarlier V.
    J Antimicrob Chemother; 1994 Apr 01; 33(4):729-35. PubMed ID: 8056691
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of antibacterial activities of meropenem and six other antimicrobials against Pseudomonas aeruginosa isolates from North American studies and clinical trials.
    Iaconis JP, Pitkin DH, Sheikh W, Nadler HL.
    Clin Infect Dis; 1997 Feb 01; 24 Suppl 2():S191-6. PubMed ID: 9126693
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparative in-vitro activity of biapenem against enterobacteria with beta-lactamase-mediated antibiotic resistance.
    Chen HY, Livermore DM.
    J Antimicrob Chemother; 1994 Mar 01; 33(3):453-64. PubMed ID: 8040111
    [Abstract] [Full Text] [Related]

  • 19. Effect of beta-lactamase expression on susceptibility of local isolates of Enterobacter cloacae, Serratia marcescens and Pseudomonas aeruginosa to beta-lactam antibiotics.
    Ramadan MA, Tawfik AF, Shibl AM.
    Chemotherapy; 1995 Mar 01; 41(3):193-9. PubMed ID: 7656665
    [Abstract] [Full Text] [Related]

  • 20. Comparison of imipenem and meropenem antibiotics for the MALDI-TOF MS detection of carbapenemase activity.
    Rotova V, Papagiannitsis CC, Skalova A, Chudejova K, Hrabak J.
    J Microbiol Methods; 2017 Jun 01; 137():30-33. PubMed ID: 28390706
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.